Search:
Filter:
Sort:
Novartis and Genentech have filed a Lanham Act complaint against an alternative funding program and a Canadian pharmacy allegedly supplying Canadian Xolair to Michigan patients.
Washington State investigators found serious violations at a Mochi Health-affiliated compounding pharmacy producing GLP-1s, and a med spa bill in Indiana hears public testimony about a med spa bill.
Industry experts told us that these two companies are on the FDA’s Green List, despite problematic inspections in late 2024 and early 2025. Learn what the inspectors found.
Prescription Drug Affordability Board Activity, January 2026 Activities Summary Colorado: At its January meeting, the PDAB discussed ways to improve patient engagement and agreed to accept the dismissal of Amgen v. Mizner. The board’s next meeting will be February 20, 2026. Maryland: Maryland’s next PDAB meeting will be February 23, 2026 at 9:00 AM ET. Oregon: In January, Oregon’s PDAB…
Well-meaning advocates continue to propose importing medicine from foreign countries to lower drug prices for Americans. Past efforts didn’t pay off financially and raised public health risks. Here’s the state of this issue today.
A Pennsylvania compounding pharmacy received another FDA warning letter following a series of enforcement actions, including a $1 million state fine in October.
The last two months of 2025 saw thousands of shipments of drugs popularized by social media imported into the U.S., as well as Xarelto and antibiotics. The shipments carried a wide range of product codes; some appropriate, and others far less so.
On February 17, PSM submitted written and oral testimony in opposition to Colorado HB26-1056, which would permit self-insured employers to use alternative funding programs to import foreign medicines from outside the U.S. drug supply chain.
Unregulated pill presses and molds make fake pills with dangerous and even deadly consequences for thousands of people every year. Read our July 2025 to January 2026 update about pill press seizures, policy developments, and legislation.
The FDA has posted a notice about the recall of continuous glucose monitors from Abbott.